Endocrine-targeting therapies, like estrogen receptor-α (ER) blockade or aromatase inhibitors (AI), either block ER activity or suppress estrogen biosynthesis, inhibiting the growth of ER+ breast cancer cells (Terrisse et al, 2023). This evidence concerns the gene ESR1 and breast carcinoma.